$ cat ./records/gates-foundation-supports-modular-b-life-diagnostic-laboratory-in-2015.txt
Gates Foundation Supports Modular B-LiFE Diagnostic Laboratory in Guinea
[RECORD.TXT] · cat --full
During the West Africa Ebola outbreak, Gates Foundation funding supported deployment of the B-LiFE (Biological Light Fieldable Laboratory for Emergencies), a modular tent-based BSL-3 diagnostic laboratory that operated on-site at the N'Zerekore Ebola Treatment Centre in Guinea for three months. The facility processed Ebola PCR tests in the field, eliminating transport delays to central labs and accelerating patient triage. Its deployment demonstrated a replicable model for field diagnostics in low-resource outbreak settings that has since been cited in preparedness planning for future hemorrhagic fever responses.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Launches $75 Million Child Health and Mortality Surveillance Network
Next →
Gates Foundation Supports Ebola ça Suffit Ring Vaccination Phase III Trial
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.